Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 435 participants.

Also called NCT01693029

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 435 participants (enrolled count) (from the registry)
Sponsor
Sandoz (from the registry)
Registry
  • NCT NCT01693029
Other papers using this trial's data
  • A Comparison of the Safety and Efficacy of HX575 (Epoetin Alfa Proposed Biosimilar) with Epoetin Alfa in Patients with End-Stage Renal Disease American journal of nephrology, 2017 DOI, PubMed 29084409

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01693029. Randomized; quadruple masking; primary purpose treatment. Start 2012-09 (registry gives no type); primary completion 2014-05 (actual). Results posted on 2017-05-12.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
Acronym
ACCESS
Condition
Anemia
Intervention (Drug)
HX575 epoetin alfa
Intervention (Drug)
US-licensed epoetin alfa
Lead sponsor
Sandoz (class: industry)

Record details

Record id
cardio:ct-nct01693029
Content hash
7c455b6145ec4809620c32d02fd43d0e8873f72a862d4393297e50f0f4dca105